Results 131 to 140 of about 9,558 (217)

Cabotegravir and rilpivirine for treatment of HIV infection in Africa: week 96 results from the phase 3b randomized, open-label, noninferiority CARES trial. [PDF]

Nat Med
Kityo C, Mambule IK, Musaazi J, Sokhela S, Mugerwa H, Yawe I, Cresswell F, Siika A, Kosgei J, Shah R, Naidoo L, Opiyo K, Otike C, Möller K, Okwero M, Wambui C, Van Eygen V, Mohammed P, Addo Boateng F, Paton NI, CARES trial team.   +20 more
europepmc   +1 more source

Exploring the Interaction Between Injection Site and Biological Sex on the Real-world Population Pharmacokinetics of Long-acting Cabotegravir and Rilpivirine in People With HIV. [PDF]

Open Forum Infect Dis
Tan B, John M, Castley A, Williams L, Joyce D, Nolan D, O'Halloran S, Salman S.   +7 more
europepmc   +1 more source

Long-acting Cabotegravir/Rilpivirine for Treatment of HIV During Pregnancy: A Case Series. [PDF]

Open Forum Infect Dis
Sunagawa SW, Floyd CC, Bares SH, Podany AT, Scarsi KK, Mykris T, Winchester L, O'Neill J, Kubat M, Tran C, Davis JM, Snyder JW, Havens JP.   +12 more
europepmc   +1 more source

Clinical Consequences of Delaying Implementation of Long-Acting Antiretroviral Therapy for People With HIV and Persistent Viremia in the United States. [PDF]

Clin Infect Dis
Pei PP, Jones M, Hu R, Chen W, Sax PE, Pandya A, Gandhi M, Eron JJ, Currier JS, Wilkin TJ, Reddy KP, Qoshe L, Hyle EP, Freedberg KA.   +13 more
europepmc   +1 more source

Bimonthly Administered Long-Acting Cabotegravir and Rilpivirine Are Highly Effective and Well-Tolerated in People With Human Immunodeficiency Virus Above 65 Years. [PDF]

Open Forum Infect Dis
Calcagno A, Candela C, Riva A, Calza S, Fioretti B, Gardini S, Milic J, Celesia BM, Orofino G, De Vito A, De Socio GV, Cossu MV, Barrera F, Mazzitelli M, Nozza S, Guaraldi G, Focà E, GEPPO Study Group .   +17 more
europepmc   +1 more source

Predicting Utility of Long-Acting Injectables in Paediatric Patients With PBPK Models [PDF]

, 2016
Back, D, Owen, A, Rajoli, RKR, Rannard, S, Siccardi, M   +4 more
core  

Efficacy and Safety of Cabotegravir-Rilpivirine in PLWH: A Real-World Study. [PDF]

Viruses
Conti GN, Spampinato S, De Vito A, Marino A, Cirelli T, Coco V, Mirabile A, Fontana Del Vecchio R, Franco A, Montineri A, Fasca C, Gullotta C, Paternò Raddusa MS, Russotto Y, Sofia S, Pantò G, Calì C, Bruno R, Pistarà E, Villari N, Iacobello C, Cacopardo B, Celesia BM, Pellicanò GF, Antonucci FP, Lo Caputo S, Madeddu G, Nunnari G, Venanzi Rullo E.   +28 more
europepmc   +1 more source

Subcutaneous injections of cabotegravir plus rilpivirine long-acting in virally suppressed adults with HIV-1. [PDF]

AIDS
D'Amico R, Han K, Min S, DeMoor R, St Clair M, Ford SL, Harrington C, Bernal-Morell E, Lombaard J, Crauwels H, Kolobova I, Patel N, Jamil N, Van Solingen-Ristea R, Acuipil C, Spreen W.   +15 more
europepmc   +1 more source